|
|
|
| Effect of Lianlian Capsules on Helicobacter pylori related chronic non-atrophic gastritis with syndrome of dampness-heat of spleen and stomach |
| SHI Songyan SUN Yongshun LI Yiping |
Department of Spleen and Stomach Disease, Shanghai Municipal of Tradition Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China
|
|
|
|
Abstract Objective To observe the clinical effect of Lianlian Capsules on Helicobacter pylori (Hp) related chronic non-atrophic gastritis with syndrome of dampness-heat of spleen and stomach. Methods A total of 78 patients with Hp related chronic non-atrophic gastritis with syndrome of dampness-heat of spleen and stomach admitted to the Department of Spleen and Stomach Diseases of Shanghai Municipal of Tradition Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine from June 2021 to March 2022 were selected and divided into control group and treatment group according to random number table method, with 39 cases in each group. The control group was treated with Bismuth quadruple therapy, and the treatment group was treated with Lianlian Capsules on the basis of the control group. The course of treatment in both groups was 14 days. The Hp eradication rate, clinical efficacy, safety, and tradition Chinese medicine syndrome score and interleukin (IL)-8 before and after treatment were compared between the two groups. Results In the course of treatment, four patients in the treatment group and four patients in the control group withdrew. There was no significant difference in Hp eradication rate between the two groups (P＞0.05). The clinical effect of the treatment group was better than that of the control group, and the difference was statistically significant (P＜0.05). After treatment, traditional Chinese medicine syndrome score in two groups were lower than before treatment, and the treatment group was lower than the control group, the differences were statistically significant (P＜0.05). After treatment, IL-8 level in the treatment group was lower than that in the treatment group before treatment and control group, and the differences were statistically significant (P＜0.05). There were no abnormalities in blood routine and liver and kidney function in the two groups during treatment. Conclusion Lianlian Capsules combined with Bismuth quadruple therapy in the treatment of Hp related chronic non-atrophic gastritis with syndrome of dampness-heat of spleen and stomach has a good effect, can improve clinical symptoms, reduce the level of inflammatory factor IL-8, and the drug use is safe.
|
|
|
|
|
|
[1] 国家消化系统疾病临床医学研究中心（上海），国家消化道早癌防治中心联盟，中华医学会消化病学分会幽门螺杆菌学组，等.中国幽门螺杆菌根除与胃癌防控的专家共识意见（2019年上海）[J].中华健康管理学杂志，2019， 13（4）：285-291.
[2] 张学智，魏玮，蓝宇.成人幽门螺杆菌引起的胃炎中西医协作诊疗专家共识（2020，北京）[J].中医杂志，2020，61（22）：2016-2024.
[3] Hooi JKY，Lai WY，Ng WK，et al. Global Prevalence of Helicobacter pylori Infection：Systematic Review and Meta- Analysis [J]. Gastroenterology，2017：420-429.
[4] 张万岱，胡伏莲，萧树东，等.中国自然人群幽门螺杆菌感染的流行病学调查[J].现代消化及介入诊疗，2010，15（5）：265-270.
[5] 刘文忠.“幽门螺杆菌胃炎京都全球共识”解读[J].胃肠病学，2015，20（8）：449-456.
[6] 奚肇宏，夏军权，滑永志.中药治疗幽门螺杆菌相关性胃炎的研究进展[J].南京中医药大学学报，2018，34（4）：429-432.
[7] 中华医学会，中华医学会杂志社，中华医学会消化病学分会，等.慢性胃炎基层诊疗指南（2019年）[J].中华全科医师杂志，2020，19（9）：768-775.
[8] 刘文忠，谢勇，陆红，等.第五次全国幽门螺杆菌感染处理共识报告[J].胃肠病学，2017，22（22）：346-360.
[9] 张声生，唐旭东，黄穗平，等.慢性胃炎中医诊疗专家共识意见（2017）[J].中华中医药杂志，2017，32（7）：3060- 3064.
[10] 胡伏莲，张声生.全国中西医整合治疗幽门螺杆菌相关“病-证”共识[J].胃肠病学和肝病学杂志，2018，27（9）：1008-1016.
[11] 徐艳琴，朱海超，李进，等.不同药物方案治疗幽门螺杆菌阳性慢性胃炎活动期患者的临床疗效及安全性[J].安徽医学，2019，40（3）：244-247.
[12] 赵娜，李岩.小建中胶囊四联疗法根除幽门螺杆菌的疗效及相关症状的改善情况[J].中国中西医结合消化杂志，2019，27（2）：143-146.
[13] 马卫娥，肖劲.成人幽门螺杆菌感染的现状及分析[J].中国实用医药，2020，15（28）：173-175.
[14] Amin T. Diagnosis of Helicobacter pylori Using Invasive and Noninvasive Approaches [J]. J Pathog，2018，2018：1- 13.
[15] 梁敏，周晓虹.幽门螺杆菌相关性胃病的中医证型研究概况[J].中医研究，2020，33（9）：66-70.
[16] 杨闪闪，张学智，叶晖，等.从幽门螺杆菌感染视角新解“邪之所凑，其气必虚”[J].湖南中医药大学学报，2020， 40（8）：929-932.
[17] 何聪，王慧超，周秉舵，等.清化和中方加减治疗脾胃湿热型慢性非萎缩性胃炎的临床疗效观察[J].上海中医药杂志，2021，55（2）：56-58，62.
[18] 易惺钱，敖梅英，乐毅敏，等.基于文献研究的中医药抗幽门螺杆菌的作用机理探析[J].江西中医药大学学报，2021，33（3）：38-43.
[19] 刘新杨，商亚珍.半枝莲提取黄酮类化合物药理学研究进展[J].承德医学院学报，2021，38（5）：421-426.
[20] 刘晓金，李子静，房绍龙，等.连翘化学成分及药理作用的研究[J].山东医学高等专科学校学报，2021，43（4）：308-309.
[21] 张晓娟，左冬冬.白术化学成分及药理作用研究新进展[J].中医药信息，2018，35（6）：101-106.
[22] 陈振鹤，吴国泰，任远.枳壳的化学成分·药理作用及临床应用[J].安徽农业科学，2016，44（26）：95-97.
[23] 谢珺，胡雨涛，叶欣，等.中药白及的药理活性及在新型创伤敷料方面的应用[J].海南医学，2022，33（3）：371- 373.
[24] 关秀锋，王锐，曲秀芬，等.延胡索的化学成分与药理作用研究进展[J].化学工程师，2020，34（3）：57-60.
[25] 张毅.连翘对内毒素作用下大鼠脾脏淋巴细胞TLR4、NF-κB、IL-6及IL-10的影响[D].太原：山西医科大学，2014.
|
|
|
|
